Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study (original) (raw)
Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia
Ole Faergeman
American Heart Journal, 2005
View PDFchevron_right
Comparative efficacy study of atorvastatin vs. simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia
Salvatore Turco
Diabetes, Obesity and Metabolism, 2000
View PDFchevron_right
The lipid-lowering effect of atorvastatin in Taiwanese diabetic patients with hyperlipidemia
Wayne H.-h. Sheu
Tzu Chi Medical Journal, 2013
View PDFchevron_right
Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded—end point (probe) trial
Massimo Barrella, Rosanna Toscano
Current Therapeutic Research, 2004
View PDFchevron_right
Effects of atorvastatin 10 mg/d on insulin resistance: A 12-week, open-label study in hyperlipidemic patients
Oguz Yavuzgil
Current Therapeutic Research, 2006
View PDFchevron_right
Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease
Ingar Holme
The American journal of cardiology, 2002
View PDFchevron_right
Comparative Study of Efficacy of Atorvastatin 40 Mg Daily Rosuvastatin 20 Mg Daily And Rosuvastatin 20 Mg Alternate Day Day ,Among Diabetic Patients.A Study Of 300 Patients
Mukul Misra
IOSR Journal of Dental and Medical Sciences, 2017
View PDFchevron_right
Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein …
Massimo Barrella
Current therapeutic …, 2004
View PDFchevron_right
Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin
J. Ducobu, Yvon Carpentier
International Journal of Cardiology, 2005
View PDFchevron_right
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia
Gabriele Bittolo Bon
Atherosclerosis, 1997
View PDFchevron_right
Comparison of Lipid Lowering Effects of Rosuvastatin and Atorvastatin in Type 2 Diabetic Patients with Primary Hyperlipidemia
Maria Yousaf
Pakistan Armed Forces Medical Journal, 2020
View PDFchevron_right
Efficacy and Safety of Atorvastatin in Dyslipidemic Patients at Tertiary Care Hospital
Mrs. Geetanjali Salimath
Biochemistry & Pharmacology: Open Access, 2018
View PDFchevron_right
Efficacy of Atorvastatin and Gemfibrozil, Alone and in Low Dose Combination, in the Treatment of Diabetic Dyslipidemia
Jordi ordonez-llanos
The Journal of Clinical Endocrinology & Metabolism, 2003
View PDFchevron_right
The Comparison of Simvastatin and Atorvastatin Efficacy in Lowering Lipid Profile and Apolipoprotein-B of Diabetic Dyslipidemia Patient
Sony Wibisono
2013
View PDFchevron_right
Comparison of Safety and Eficacy of Rosuvastatin (10 Mg) And Atorvastatin (30Mg) in Cases of Dyslipidemia over Twelve Weeks of Treatment
Professor B kumar
View PDFchevron_right
Effective Analysis of Atorvastatin Versus in Simvastatin Patients with Hyperlipidemia
JAWAHAR FAROOK
2009
View PDFchevron_right
Effects of Atorvastatin and Rosuvastatin on glycemic parameters of dyslipidemic patients: A prospective study
Jameel Ahmad
Asian Journal of Pharmacy and Pharmacology, 2020
View PDFchevron_right
Lipid modifying action of atorvastatin in escalating doses in patients of coronary artery disease
Sajjad Hossain
International Journal of Basic & Clinical Pharmacology, 2014
View PDFchevron_right
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia
Michael D A V I D S O N Wau
The American Journal of Cardiology, 2001
View PDFchevron_right
The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)
Andrew Neil
Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease, 2008
View PDFchevron_right
Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia
Ji-yong Choi
The Korean journal of internal medicine, 2010
View PDFchevron_right
A Comparative Study to Evaluate Efficacy and Safety of Daily Dosing versus Alternate-Day Atorvastatin Therapy in Patients with Dyslipidemia
Dr. Syed Salman Farookh, MD
Pharmacology and Clinical Pharmacy Research
View PDFchevron_right
Effect of atorvastatin on highdensity lipoprotein cholesteroland its relationship withcoronary events: a subgroupanalysis of the GREekAtorvastatin and Coronary-heart-disease Evaluation (GREACE) Study
Vasilios Athyros
Current Medical Research and Opinion, 2004
View PDFchevron_right
A brief review paper of the efficacy and safety of atorvastatin in early clinical trials
James Best
Atherosclerosis, 1997
View PDFchevron_right
Effects of Increasing Doses of Atorvastatin on the Atherogenic Lipid Subclasses Commonly Associated With Hypertriglyceridemia
Don Luo
The American Journal of Cardiology, 2007
View PDFchevron_right
Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients
Michael J Quon
Journal of the American College of Cardiology, 2010
View PDFchevron_right
Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)
Helen Colhoun, M. Szarek
Clinical Chemistry, 2009
View PDFchevron_right
Effects of Low-Dose Atorvastatin and Rosuvastatin on Plasma Lipid Profiles
Claudia Stefanutti
American Journal of Cardiovascular Drugs, 2008
View PDFchevron_right
Comparison of Clinical Effectiveness of Atorvastatin and Rosuvastatin Among High-Risk Patients with Dyslipidaemia
hammad bhatti
Pakistan Journal of Medical and Health Sciences, 2022
View PDFchevron_right
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: The treat-to-target (3T) study
Mogens Larsen
Clinical Therapeutics, 2003
View PDFchevron_right